NUVBNuvation Bio Inc - Ordinary Shares - Class A
$5.70
$0.28
(5.17%)
Closed $5.70
$0.00
(0.00%)
After Hours
EarningsAug 6
Mkt Cap$1.89B
Vol6.33M
Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?
Key PointsAccording to a Form 4 filing, a Nuvation Bio executive reported selling 125,000 Class A shares for a total value of $753,000 on June 23, 2026...
Nasdaq News: Markets
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced...
PR Newswire
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE...
PR Newswire
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
Nuvation Bio Announces Proposed Convertible Senior Notes Offering Nuvation Bio Announces Proposed Convertible Senior Notes Offering PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on...
PR Newswire
Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum
Key PointsDirector Robert Mashal purchased 25,000 shares at a price of $4.73 per share on June 9, 2026...
Nasdaq News: Markets
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
Nuvation Bio to Present at the Jefferies Global Healthcare Conference Nuvation Bio to Present at the Jefferies Global Healthcare Conference PR Newswire NEW YORK, May 27, 2026 NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of...
PR Newswire
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer...
PR Newswire
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer Nuvation Bio to Collaborate with Thermo Fisher...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest NUVB News
ViewNuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?
Nasdaq News: Markets
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Zacks
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
PR Newswire
Advertisement|Remove ads.